Interpretation of the Kidney Disease: Improving Global Outcomes guidelines for iron therapy: commentary and emerging evidence

被引:5
作者
Berns, Jeffrey S. [1 ]
机构
[1] Univ Penn, Dept Med, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
anaemia; CKD; ESA; ESRD; iron; CLINICAL-PRACTICE GUIDELINE; SODIUM FERRIC GLUCONATE; HIGH SERUM FERRITIN; HEMODIALYSIS-PATIENTS; INTRAVENOUS IRON; DEFICIENCY ANEMIA; OXIDATIVE STRESS; MANAGEMENT; REQUIREMENTS; FERUMOXYTOL;
D O I
10.1093/ckj/sfx042
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The 'Kidney Disease: Improving Global Outcomes' (KDIGO) Clinical Practice Guideline for Anaemia in Chronic Kidney Disease includes detailed recommendations for the use of iron therapy in a variety of clinical circumstances. However, the evidence base regarding the use of iron therapy in patients with chronic kidney disease was relatively incomplete at the time the guideline was developed. As a result, there has been significant debate as to the appropriate use of iron therapy in this population. In this article, the KDIGO guidelines are discussed in the context of recently published commentary pieces and additional research to provide a richer context in which to interpret and understand the guidelines.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 44 条
  • [1] A randomized trial of intravenous and oral iron in chronic kidney disease
    Agarwal, Rajiv
    Kusek, John W.
    Pappas, Maria K.
    [J]. KIDNEY INTERNATIONAL, 2015, 88 (04) : 905 - 914
  • [2] [Anonymous], 2001, Am J Kidney Dis, V37, pS182
  • [3] [Anonymous], AN MAN CHRON KIDN DI
  • [4] Safety of intravenous iron in clinical practice: Implications for anemia management protocols
    Aronoff, GR
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (12): : S99 - S106
  • [5] Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
    Auerbach, Michael
    Ballard, Harold
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, : 338 - 347
  • [6] A study of parenteral iron regimens in hemodialysis patients
    Besarab, A
    Kaiser, JW
    Frinak, S
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (01) : 21 - 28
  • [7] Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients
    Canavese, C
    Bergamo, D
    Ciccone, G
    Longo, F
    Fop, F
    Thea, A
    Martina, G
    Piga, A
    [J]. KIDNEY INTERNATIONAL, 2004, 65 (03) : 1091 - 1098
  • [8] Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients' response to IV iron with elevated ferritin (DRIVE) study
    Coyne, Daniel W.
    Kapoian, Toros
    Suki, Wadi
    Singh, Ajay K.
    Moran, John E.
    Dahl, Naomi V.
    Rizkalal, Adel R.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (03): : 975 - 984
  • [9] Iron requirements in erythropoietin therapy
    Eschbach, JW
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (02) : 347 - 361
  • [10] Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease
    Ferrari, Paolo
    Kulkarni, Hemant
    Dheda, Shyam
    Betti, Susanne
    Harrison, Colin
    St Pierre, Timothy G.
    Olynyk, John K.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (01): : 77 - 83